Wallace Advisory Group LLC Sells 65 Shares of Johnson & Johnson (NYSE:JNJ)

Wallace Advisory Group LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 6,733 shares of the company’s stock after selling 65 shares during the period. Wallace Advisory Group LLC’s holdings in Johnson & Johnson were worth $1,091,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $27,000. MFA Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $43,000. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $44,000. Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson during the second quarter valued at approximately $46,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 30th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Down 0.1 %

Shares of JNJ stock traded down $0.21 during trading on Friday, reaching $160.29. The company’s stock had a trading volume of 5,331,694 shares, compared to its average volume of 7,091,981. The business has a fifty day moving average price of $162.60 and a 200-day moving average price of $154.33. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market cap of $385.77 billion, a price-to-earnings ratio of 9.99, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.